GleamWall
中文EN

ARTV Artiva Biotherapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1817241 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-23.9%
TTM EPS YoY-129.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-43.6%
ROA-39.9%
ROIC (approx.)-45.8%
Asset turnover—

Leverage & solvency

Liabilities / assets6.5%
Debt / equity0.00x
Current ratio19.88x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-5.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———————$0
R&D expense$25.99M$21.93M$19.31M$16.99M$17.63M$17.86M$17.05M$13.32M
SG&A expense$5.96M$4.96M$5.12M$4.94M$5.26M$4.95M$5.12M$4.95M
Operating income-$31.95M-$26.89M-$24.43M-$21.93M-$22.90M-$22.81M-$22.17M-$18.27M
Net income-$28.82M-$25.00M-$23.52M-$20.77M-$21.53M-$21.25M-$20.31M-$16.09M
EBITDA-$31.25M-$26.19M-$23.76M-$21.27M-$22.30M-$22.21M-$21.54M-$17.65M
EPS (basic)-0.56-0.63-0.95—-0.88-0.87-0.83—
EPS (diluted)-0.56-0.63-0.95—-0.88-0.87-0.83—
Weighted avg. shares (diluted)51.20M39.41M24.68M—24.48M24.38M24.34M—
Balance sheet
Cash & equivalents$61.23M$301.45M$20.95M$26.70M$25.51M$28.47M$30.40M$40.49M
Short-term investments$257.87M$47.94M$65.83M$81.31M$97.46M$113.90M$135.56M$145.19M
Receivables———————$0
Current assets$326.25M$352.28M$88.74M$112.67M$129.52M$149.07M$170.00M$188.63M
PP&E, net$6.17M$5.67M$6.22M$6.62M$6.98M$6.89M$7.06M$6.37M
Total assets$342.98M$368.63M$105.95M$130.94M$148.86M$169.39M$191.26M$209.58M
Current liabilities$16.41M$14.58M$10.88M$13.09M$11.12M$10.77M$12.20M$12.25M
Total liabilities$22.26M$21.13M$18.11M$20.97M$19.64M$20.35M$22.48M$22.94M
Shareholders' equity$320.72M$347.50M$87.85M$109.97M$129.22M$149.04M$168.78M$186.64M
Cash flow statement
Operating cash flow-$28.45M-$20.36M-$20.95M-$14.73M-$19.20M-$22.98M-$19.84M-$14.65M
Capital expenditure$1.04M$415,000$242,000$421,000$600,000$1.05M$511,000$64,000
Free cash flow-$29.49M-$20.77M-$21.19M-$15.15M-$19.80M-$24.04M-$20.35M-$14.71M
Investing cash flow-$211.70M$17.59M$15.32M$16.04M$16.28M$21.12M$9.97M-$966,000
Financing cash flow-$26,000$283.27M-$112,000-$121,000-$37,000-$72,000$239,000-$30,000
Depreciation & amortization$700,000$700,000$666,000$666,000$600,000$600,000$628,000$614,000
Stock-based compensation$2.80M$2.80M$1.59M$1.59M$1.63M$1.63M$2.05M$2.18M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.